ClinicalTrials.gov record
Completed Phase 2 Interventional

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

ClinicalTrials.gov ID: NCT00042679

Public ClinicalTrials.gov record NCT00042679. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 30, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT00042679
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

  • Carboplatin Drug
  • Gemcitabine Drug
  • LY900003 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2002
Primary completion
Not listed
Completion
Not listed
Last update posted
Jul 18, 2006

Started 2002

United States locations

U.S. sites
11
U.S. states
8
U.S. cities
11
Facility City State ZIP Site status
Not listed Bakersfield California
Not listed Berkeley California
Not listed Torrance California
Not listed Miami Beach Florida
Not listed Chicago Illinois
Not listed Park Ridge Illinois
Not listed Baltimore Maryland
Not listed Chattanooga Tennessee
Not listed Lubbock Texas
Not listed Charlottesville Virginia
Not listed Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00042679, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 18, 2006 · Synced Apr 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00042679 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →